ICI in combination with TROP2-directed ADCs may be an attractive option for certain TACSTD2-high tumors, such as MSI-high CRC and hepatocellular cancer, where ICI has already seen success. This evidence concerns the gene TACSTD2 and hepatocellular carcinoma.